Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial
Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial
复制标题
DOI：
10.3945/ajcn.112.049221
复制
发表时间：
2013-10-01
影响因子：
7.1
通讯作者：
Vichinsky, Elliott P.
中科院分区：
文献类型：
--
作者：
Fung, Ellen B.;Kwiatkowski, Janet L.;Vichinsky, Elliott P.
目的：探讨补锌对地中海贫血患者骨量的影响。设计：42例地中海贫血患者(女性21例，年龄10~30岁)随机分为补锌组和安慰剂组，每日补锌25 mg。用双能X线骨密度仪测定骨矿含量(BMC)和面骨密度(ABMD)，并在0、12、18个月采集空腹血测定血锌。结果：32名受试者完成研究，平均+/-SD为17.1+/-5.2年，81%的受试者依赖输液。血浆锌是
Background: Patients with thalassemia major (Thal) frequently have low plasma zinc, which has been associated with low bone mass.Objective: The objective was to determine the effect of zinc supplementation on bone mass in patients with Thal.Design: Forty-two subjects (21 females aged 10-30 y) with Thal and low bone mass were randomly assigned to receive 25 mg Zn/d or placebo. Bone mineral content (BMC) and areal bone mineral density (aBMD) were assessed by using dual-energy X-ray absorptiometry, and fasting blood was collected for the measurement of plasma zinc at 0, 12, and 18 mo.Results: Thirty-two subjects, 81% of whom were transfusion dependent, completed the study (mean +/- SD: 17.1 +/- 5.2 y). Plasma zinc was